Antimicrobial susceptibility of pneumococcal isolates causing bacteraemic pneumococcal pneumonia: Analysis using current breakpoints and fluoroquinolone pharmacodynamics

International Journal of Antimicrobial Agents

Volumn 36, Issue 1, 2010, Pages 95-97

  Feldman, C ^a,c,d   Brink, A J ^b   von Gottberg, A ^c   Wolter, N ^c   de Gouveia, L ^c   Perovic, O ^c   Klugman, K P ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b MILPARK HOSPITAL   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PENICILLIN G; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TELITHROMYCIN;

ADULT; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 77953024694     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.02.021     Document Type: Letter

References (7)

1. Von Gottberg A., Klugman K.P., Cohen C., Wolter N., de Gouveia L., du Plessis M., et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 2008, 371:1108-1113.
2. Lacy M.K., Lu W., Xu X., Tessier P.R., Nicolau D.P., Quintiliani R., et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999, 43:672-677.
3. Chien S.-C., Rogge M.C., Gisclon L.G., Curtin C., Wong F., Natarajan J., et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997, 41:2256-2260.
4. Fish D.N., Chow A.T. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997, 32:101-119.
5. Chien S.C., Wong F.A., Fowler C.L., Callery-D'Amico S.V., Williams R.R., Nayak R., et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in health volunteers. Antimicrob Agents Chemother 1998, 42:885-888.
6. Schentag J.J., Gilliland K.K., Paladino J.A. What have we learned from pharmacokinetic and pharmacodynamic theories?. Clin Infect Dis 2001, 32(Suppl. 1):S39-S46.
7. Wolter N., von Gottberg A., du Plessis M., de Gouveia L., Klugman K.P. Molecular basis and clonal nature of increasing pneumococcal macrolide resistance in South Africa, 2000-2005. Int J Antimicrob Agents 2008, 32:62-67. Group for Enteric, Respiratory and Meningeal Surveillance in South Africa.